GVAX cancer vaccine data

Researchers presented preliminary data on SOMA's Phase I/II trial of GVAX in advanced melanoma at the Molecular Medicine Society meeting in Washington. The vaccine consists of a patient's own cells or a tumor cell line modified to express GM-CSF. Biopsies of vaccine sites, DTH tests and metastatic tumor sites showed that immune system cells had been stimulated by vaccination. DTH tests evaluate patients' ability to react to their own irradiated tumor tissue when placed under the skin. ...